ArticleAdvanced biomedical research2025
Analysis of the Results of Hepatitis B and C Molecular Tests in Southern Iran from 2018 to 2022, the Possibility of Hepatitis C Genotype Change in the Region.
Article in Advanced biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to investigate the prevalence of hepatitis B and C viruses in patients at the Shahid Motahari Clinic in Shiraz, Iran, from 2018 to 2022 using molecular diagnostic tests. Materials and Methods: This cross-sectional study was conducted on patients who underwent polymerase chain reaction (PCR) molecular tests for the diagnosis of hepatitis B and C at the Shahid Motahari Clinic in Shiraz. A total of 538 PCR tests for hepatitis B and 457 tests for hepatitis C were administered. Among them, 69 patients diagnosed with hepatitis B virus (HBV) and 60 patients with HCV were selected for examination, and their clinical data were collected. Results: The prevalence of HBV and hepatitis C virus (HCV) in the study population was 17.28% and 20.56%, respectively. Most infected patients were male, married, and of Fars ethnic background. The main risk factors for HBV were extramarital sex and a family history of hepatitis B or C, whereas the main risk factors for HCV included drug injection, blood transfusion, imprisonment, tattooing, and extramarital sex. The findings revealed that the two most common HCV subtypes were subtype 3b (72%) and subtype 1a (28%). Conclusion: The results showed that 17.28% of participants had HBV and 20.56% had HCV. The majority of those with HBV or HCV were male, Fars, and married. Patients with HBV had a high incidence of family members with hepatitis B/C, whereas those with HCV had a high incidence of transfusion, drug injection, tattooing, and imprisonment. The most common HCV subtypes were 3b and 1a.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.